Ocular Therapeutix (OCUL) had the highest return in February 2023 by a mid-cap US stock or mid-cap US stock, returning 54.5%.
| ASSET | MONTH | % RETURN |
|---|---|---|
Ocular Therapeutix (OCUL) | February 2023 | 54.48% |
Innodata (INOD) | February 2023 | 52.25% |
Eos Energy Enterprises (EOSE) | February 2023 | 51.03% |
SoundHound AI (SOUN) | February 2023 | 48.68% |
Oscar Health (OSCR) | February 2023 | 44.65% |
VEON (VEON) | February 2023 | 42.46% |
Intapp (INTA) | February 2023 | 36.62% |
Frontline (FRO) | February 2023 | 32.96% |
International Seaways (INSW) | February 2023 | 31.56% |
ELF Beauty (ELF) | February 2023 | 30.25% |
Lantheus (LNTH) | February 2023 | 28.38% |
TransMedics (TMDX) | February 2023 | 27.83% |
Cipher Mining (CIFR) | February 2023 | 26.67% |
Viking Therapeutics (VKTX) | February 2023 | 24.97% |
Scorpio Tankers (STNG) | February 2023 | 24.94% |
Apellis Pharmaceuticals (APLS) | February 2023 | 24.46% |
Vita Coco (COCO) | February 2023 | 24.34% |
Materion (MTRN) | February 2023 | 24.1% |
Celcuity LLC (CELC) | February 2023 | 24% |
Cidara Therapeutics (CDTX) | February 2023 | 22.76% |
Protagonist Therapeutics (PTGX) | February 2023 | 22.14% |
MYR (MYRG) | February 2023 | 21.94% |
Bausch Health Companies (BHC) | February 2023 | 21.38% |
Merus (MRUS) | February 2023 | 20.85% |
Remitly Global (RELY) | February 2023 | 20.81% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
